2021-01-06,VistaGen Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
2020-12-30,VistaGen Announces Publication in CNS Spectrums Detailing Proposed Mechanism of Action of Its Investigational Neuroactive Nasal Sprays for Anxiety and Depression Disorders
2020-12-22,VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering
2020-12-18,VistaGen Therapeutics Announces Pricing of Underwritten Public Offering
2020-12-17,VistaGen Therapeutics Announces Proposed Underwritten Public Offering
2020-12-10,VistaGen Announces Korean Intellectual Property Office Decision to Grant PH10 Patent for Treatment of Depression
2020-12-01,"VistaGen Therapeutics Expands R&D Team with Appointment of Louis Monti, M.D., Ph.D., Pioneer in the Development of Neuroactive Steroids known as Pherines as Potential Treatments for Anxiety and Depression Disorders, as Vice President, Translational Medicine"
2020-11-19,VISTAGEN THERAPEUTIC (VSTA) Q3 2020 Earnings Call Transcript
2020-11-16,"Earnings Beat: VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts"
2020-11-12,VistaGen Therapeutics Reports Fiscal 2021 Second Quarter Financial Results and Provides Highlights on its CNS Pipeline and Business Progress
2020-11-12,VistaGen Reports Positive Preclinical Data Differentiating Mechanism of Action of PH94B from Risk-Ridden Benzodiazepines
2020-10-27,InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring VistaGen Therapeutics Inc. CEO Shawn Singh
2020-10-14,Nasdaq Grants VistaGen 180-Day Extension to Meet Minimum Bid Price Requirement
2020-09-03,VistaGen Reports Positive New Data from Second Preclinical Study of AV-101 in Combination with Probenecid
2020-08-31,(LD Micro) 360 Companies Set to Present - this Week
2020-08-27,VistaGen Therapeutics to Present at the LD Micro 500 Virtual Conference
2020-08-13,VistaGen Therapeutics Reports Fiscal 2021 First Quarter Financial Results and Highlights CNS Pipeline and Business Progress
2020-08-10,VistaGen Therapeutics Announces Exercise and Closing of Underwriters' Over-allotment Option in Underwritten Public Offering
2020-08-05,LD Micro : Announces Preliminary List of Presenters for the LD 500
2020-07-23,VistaGen Therapeutics Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94B for Acute Treatment of Anxiety in Patients with Social Anxiety Disorder
2020-06-29,VistaGen Therapeutics Reports Fiscal Year 2020 Results and Provides CNS Pipeline Update
2020-06-25,"VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia"
2020-05-27,VistaGen and Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple CNS Conditions
2020-05-18,VistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP)
2020-04-29,VistaGen Therapeutics (NASDAQ:VTGN) Is Arguably In A Tricky Situation
2020-04-28,VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19
2020-03-25,VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million
2020-02-20,VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder
2020-02-13,VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview
2020-02-11,VistaGen Therapeutics Announces Positive Preclinical Data of AV-101 Combined with Probenecid Suggesting Substantially Increased Brain Concentration Effects
2020-01-30,VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients
2019-12-19,VistaGen and Baylor College of Medicine Announce Successful Results of First-Step Target Engagement Study with VistaGen's AV-101 Focused on Treating Suicidal Ideation in Veterans
2019-12-11,VistaGen Up on Fast Track Designation for Anxiety Disorder Drug
2019-12-10,U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder
2019-12-06,"Sage Therapeutics' Depression Drug Fails in Study, Stock Down"
2019-11-20,"Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More"
2019-11-15,"The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval"
2019-11-15,VistaGen's (VTGN) Major Depressive Disorder Drug Disappoints
2019-11-14,VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder
2019-11-07,VistaGen Therapeutics Reports Fiscal 2020 Second Quarter Financial Results and Provides Pipeline Overview
2019-11-01,We're A Little Worried About VistaGen Therapeutics's (NASDAQ:VTGN) Cash Burn Rate
2019-10-28,VistaGen Therapeutics Expands European Patent Protection for AV-101 for Treatment of Depression and Dyskinesia associated with Levodopa Therapy for Parkinson's Disease
2019-10-18,These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year
2019-10-08,VistaGen Therapeutics Announces Last Patient Completes Dosing in the ELEVATE Phase 2 Clinical Study of AV-101 for Major Depressive Disorder
2019-08-15,VistaGen Therapeutics Achieves Target Patient Enrollment in the ELEVATE Study of AV-101 as an Adjunctive Treatment for Major Depressive Disorder
2019-08-13,VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results
2019-07-23,VistaGen Therapeutics Announces USPTO Grant of Patent for Treatment of Depression with Fast-Acting PH10 Neuroactive Nasal Spray
2019-06-27,"VistaGen Therapeutics, Inc. (NASDAQ:VTGN): Are Analysts Bullish?"
2019-06-25,VistaGen Therapeutics Reports Fiscal Year 2019 Results and Provides CNS Pipeline Overview
2019-06-20,"VistaGen Announces Positive Preclinical Data Supporting AV-101's Potential For Treating Levodopa-Induced Dyskinesia In Patients With Parkinson's Disease, Without The Psychological Side Effects And Safety Concerns Of Amantadine"
2019-05-30,"VistaGen Announces Positive Preclinical Data Supporting AV-101's Potential for Treating Neuropathic Pain Comparable to Pregabalin (Lyrica(R)), without its Side Effects"
2019-05-07,"VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, China"
2019-05-02,Vistagen Shares Fall Under $1 After Depression Drug Flunks Midstage Trial
2019-05-02,VistaGen Reports Top Line Results from NIMH's Exploratory Study of AV-101 Monotherapy for Treatment-Resistant Depression
2019-04-27,The VistaGen Therapeutics (NASDAQ:VTGN) Share Price Is Down 88% So Some Shareholders Are Rather Upset
2019-04-03,"VistaGen Therapeutics to Participate in the William Blair 3rd Annual Late-Stage Therapeutics Conference on April 4, 2019"
2019-04-01,"Positive Pilot Phase 3 Data Position VistaGen's PH94B Neuroactive Nasal Spray for Pivotal Phase 3 Development as a Novel, As-Needed Treatment for Social Anxiety Disorder"
2019-03-28,VistaGen Therapeutics Receives Australian Patent for Treatment of Depression with AV-101
2019-03-14,"VistaGen Therapeutics to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19, 2019"
2019-03-13,VistaGen Therapeutics Receives Notice of Allowance for Additional U.S. Patent Regarding Methods of Production for AV-101
2019-03-07,"VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019"
2019-02-27,Four Tech Stocks Looking To Test February Highs
2019-02-26,VistaGen Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
2019-02-25,VistaGen Therapeutics Announces Proposed Public Offering of Common Stock
2019-02-19,VistaGen Therapeutics Receives AV-101 Japanese Patent for Treatment of Depression and Hyperalgesia
2019-02-14,"FDA Panel Nod for J&J's Esketamine Is Good News for Allergan, Vistagen"
2019-02-13,VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10
2019-02-13,"The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering"
2019-02-12,VistaGen Therapeutics Reports Fiscal 2019 Third Quarter Financial Results
2019-02-05,"VistaGen Therapeutics to Present at the 21st Annual BIO CEO & Investor Conference on February 11, 2019"
2019-01-31,AV-101 Stimulates the Formation of New Brain Cells in Nonclinical Studies
2019-01-15,"VistaGen Therapeutics Appoints Pharmaceutical Industry Veteran, Ann Cunningham, to its Board of Directors"
2018-12-27,VistaGen Therapeutics to Present at 11th Annual Biotech Showcase
2018-12-21,"Do Institutions Own VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Shares?"
2018-11-29,VistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101
2018-11-15,"Consolidated Research: 2018 Summary Expectations for Tapestry, Mallinckrodt public limited company, Moxian, Applied Genetic Technologies, VistaGen Therapeutics, and Oasis Midstream Partners LP  Fundamental Analysis, Key Performance Indications"
2018-11-12,VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression
2018-10-29,VistaGen Therapeutics Reports Fiscal 2019 Second Quarter Financial Results
2018-10-29,"Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more"
2018-10-25,"VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depressive Disorder Demonstrated in Phase 2a Study"
2018-10-22,"VistaGen Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018"
2018-10-15,"VistaGen Therapeutics Appoints Dr. Michael Liebowitz to CNS Clinical and Regulatory Advisory Board in Preparation for Pivotal Phase 3 Development of PH94B as the First Rapid-Acting, On-Demand Treatment of Social Anxiety Disorder"
2018-10-11,"Tech and biotech on collision course, squeezed by the Peninsula's limited space"
2018-10-04,VistaGen Up on Fast Track Designation to Pain Candidate
2018-10-04,Todays Research Reports on Stocks to Watch: Pain Therapeutics and VistaGen Therapeutics
2018-10-03,VistaGen shares surge 13% after FDA grants fast track status to non-opioid pain treatment
2018-10-03,VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain
2018-09-13,VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals for As-Needed Treatment of Social Anxiety Disorder
2018-09-06,"SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating VistaGen Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors"
2018-08-14,VistaGen Therapeutics Reports Fiscal 2019 First Quarter Financial Results
2018-08-13,VistaGen Therapeutics and Baylor College of Medicine Collaborate on First-Step Study to Test VistaGens AV-101 for Potential Anti-Suicidal Effects in Veterans
2018-06-26,VistaGen Therapeutics Reports Fiscal Year 2018 Financial Results and Provides Year-to-Date Highlights
2018-06-20,Breakfast Technical Briefing on Tesaro and Three Other Additional Biotech Stocks
2018-06-13,VistaGen Therapeutics Issued Two Key U.S. Patents for Treatment of Depression with AV-101
2018-06-11,VistaGen Therapeutics Receives Notice of Allowance for Japanese Patent for Use of Stem Cells to Treat Cancer and Autoimmune Disorders
2018-05-29,Mayo Clinic-Backed NMTC Could Be Worth 3X This Year
2018-05-25,Why Vistagen Therapeutics Inc Stock Is Going Wild Today
2018-05-25,Benzinga Pro's 5 Stocks To Watch Today
2018-05-24,"Oppenheimer Feels Positive About VistaGen's 'Best-In-Class' Antidepressant, Sets $6 Target"
2018-05-23,VistaGen Therapeutics Receives Notice of Allowance of U.S. Patent for Treatment of Osteoarthritis and Joint Injuries with Stem Cell-Derived Chondrocytes and Cartilage
